By
Calgary-based Orpyx Medical Technologies, a leader in diabetic foot ulcer (DFU) and amputation prevention, has secured $20 million in growth capital. The funding round was led by Perceptive Advisors, whose Portfolio Manager, Sam Chawla, praised Orpyx as an innovator in DFU prevention.
Orpyx’s flagship product, the Orpyx® Sensory Insole system, is a cutting-edge solution that integrates multi-modal sensor technology into custom orthotics. This system provides continuous remote monitoring of critical factors such as plantar pressure, temperature, and patient activity, aiming to prevent severe foot complications in individuals with diabetes and neuropathy. A dedicated team of specialized nurses supports the monitoring process.
Dr. Breanne Everett, CEO of Orpyx, highlighted the importance of the partnership with Perceptive Advisors in driving the company’s mission. “This collaboration allows us to accelerate our efforts, saving limbs and extending mobility for those affected by diabetic foot disease,” she said.
With this new funding, Orpyx plans to expand its commercial initiatives, delivering life-changing solutions to patients and healthcare providers, ultimately improving outcomes for those most vulnerable to the serious complications of diabetes.
